Biogen to End Development of Gosuranemab in Progressive Supranuclear Palsy

By Colin Kellaher

Biogen Inc. (BIIB) Friday said it is ending development of gosuranemab for the brain disorder progressive supranuclear palsy and other primary tauopathies after a phase 2 study missed its primary endpoint.

The Cambridge, Mass., biopharmaceutical company said the main endpoint, as measured by the progressive supranuclear palsy rating scale at week 52, wasn't statistically significant, and said the study didn't show efficacy on key clinical secondary endpoints.

Biogen, which licensed gosuranemab from Bristol-Myers Squibb Co. (BMY), said it will continue a Phase 2 study of the drug for mild cognitive impairment due to Alzheimer's disease or mild AD, given differences in disease pathology.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 13, 2019 08:00 ET (13:00 GMT)

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024